RYTM
NEUTRAL
$88.69
Live
Rhythm Pharmaceuticals, Inc. · NASDAQ
Target $137.67
(+55.2%)
$55.31
52W Range
$122.2
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$6.06B
P/E
N/A
ROE
-90.5%
Profit margin
-103.6%
Debt/Equity
0.42
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
RYTM presents a classic high-growth biotech profile with a Piotroski F-Score of 4/9, indicating stable but not strong financial health. While the company boasts impressive gross margins (89.73%) and strong revenue growth (36.9%), it remains deeply unprofitable with a profit margin of -103.57%. The valuation is extremely stretched, evidenced by a Price/Sales ratio of 31.92 and a Price/Book of 42.87, suggesting the market has priced in significant future success. Despite a 'strong_buy' analyst consensus and a high target price, bearish insider activity and recent earnings misses temper the outlook.
Key Strengths
Exceptional gross margins (89.73%) indicating high product value
Strong top-line growth with 36.9% YoY revenue increase
Robust short-term liquidity with a current ratio of 4.41
Conservative leverage with a low Debt/Equity ratio of 0.42
Strong analyst backing with a target price of $137.67
Key Risks
Extreme valuation premiums (P/S 31.92, P/B 42.87)
Persistent net losses and negative operating margins (-82.20%)
Bearish insider sentiment with multiple sales by the CFO and officers
Poor recent earnings track record (only 1 beat in the last 4 quarters)
High volatility and negative 6-month price trend (-19.6%)
AI Fair Value Estimate
Based on comprehensive analysis
$113.18
+27.6% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
43
Moderate
15
78
65
55
0
AI Verdict
Speculative Growth
Key drivers: Revenue Growth, Gross Margins, Valuation Risk, Insider Selling
Confidence
80%
Value
15/100
Graham Number N/A due to lack of earnings; trades at a massive premium to book value.
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 31.92 is excessive
- P/B ratio of 42.87 indicates extreme premium
- Forward P/E is deeply negative
Future
78/100
Growth is strong, but monetization into net profit remains elusive.
Positives
- 36.9% YoY revenue growth
- Strong analyst target price ($137.67)
- High gross margin scalability
Watchpoints
- Negative earnings progression
Past
65/100
Long-term trajectory is bullish, but short-term momentum has stalled.
Positives
- 5-year price change of +337.8%
- Consistent revenue scaling
Watchpoints
- Recent 6-month decline of 19.6%
Health
55/100
Strong balance sheet liquidity offsets the lack of operational profitability.
Positives
- Current ratio 4.41
- Low Debt/Equity 0.42
Watchpoints
- Piotroski F-Score 4/9 (Stable/Mediocre)
- Negative ROE and ROA
Dividend
0/100
Typical for growth-stage biotech.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$88.69
Analyst Target
$137.67
Upside/Downside
+55.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RYTM and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Primary
|
+337.8% | +324.8% | +43.6% | -19.6% | +3.3% | +5.1% |
|
BLCO
Bausch + Lomb Corporation
Peer
|
-15.1% | -0.2% | +0.8% | +18.6% | -0.2% | -1.1% |
|
PTCT
PTC Therapeutics, Inc.
Peer
|
+52.4% | +36.8% | +52.8% | +9.8% | +8.1% | +5.4% |
|
MIRM
Mirum Pharmaceuticals, Inc.
Peer
|
+417.6% | +286.1% | +143.7% | +33.7% | +6.4% | +0.3% |
|
RGEN
Repligen Corporation
Peer
|
-39.7% | -30.0% | -7.4% | -11.9% | -5.7% | +1.3% |
RYT
Rhythm Pharmaceuticals, Inc.
Primary
5Y
+337.8%
3Y
+324.8%
1Y
+43.6%
6M
-19.6%
1M
+3.3%
1W
+5.1%
BLC
Bausch + Lomb Corporation
Peer
5Y
-15.1%
3Y
-0.2%
1Y
+0.8%
6M
+18.6%
1M
-0.2%
1W
-1.1%
PTC
PTC Therapeutics, Inc.
Peer
5Y
+52.4%
3Y
+36.8%
1Y
+52.8%
6M
+9.8%
1M
+8.1%
1W
+5.4%
MIR
Mirum Pharmaceuticals, Inc.
Peer
5Y
+417.6%
3Y
+286.1%
1Y
+143.7%
6M
+33.7%
1M
+6.4%
1W
+0.3%
RGE
Repligen Corporation
Peer
5Y
-39.7%
3Y
-30.0%
1Y
-7.4%
6M
-11.9%
1M
-5.7%
1W
+1.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-227.17
PEG Ratio
N/A
P/B Ratio
42.87
P/S Ratio
31.92
EV/Revenue
31.15
EV/EBITDA
-31.0
Market Cap
$6.06B
Profitability
Profit margins and return metrics
Profit Margin
-103.57%
Operating Margin
-82.2%
Gross Margin
89.73%
ROE
-90.45%
ROA
-27.51%
Growth
Revenue and earnings growth rates
Revenue Growth
+36.9%
Earnings Growth
N/A
Q/Q Revenue Growth
+36.87%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.42
Low debt
Current Ratio
4.41
Strong
Quick Ratio
3.92
Excellent
Cash/Share
$5.7
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
91.6%
Op. Margin
-82.2%
Net Margin
-83.0%
Total Assets
$0.5B
Liabilities
$0.2B
Equity
$0.3B
Debt/Equity
0.78x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
104%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-26
$-0.73
+6.4% surprise
2025-11-04
$-0.82
-11.7% surprise
2025-08-05
$-0.75
-12.1% surprise
Healthcare Sector Comparison
Comparing RYTM against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-90.45%
This Stock
vs
-97.42%
Sector Avg
-7.2%
(Below Avg)
Profit Margin
-103.57%
This Stock
vs
-14.95%
Sector Avg
+592.8%
(Superior)
Debt to Equity
0.42
This Stock
vs
3.06
Sector Avg
-86.4%
(Less Debt)
Revenue Growth
36.9%
This Stock
vs
147.85%
Sector Avg
-75.0%
(Slower)
Current Ratio
4.41
This Stock
vs
4.68
Sector Avg
-5.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals, Inc.
|
NEUTRAL | $6.06B | - | -90.5% | -103.6% | $88.69 | |
|
BLCO
Bausch + Lomb Corporation
|
BEARISH | $6.01B | - | -4.5% | -6.1% | $16.98 | Compare |
|
PTCT
PTC Therapeutics, Inc.
|
NEUTRAL | $6.0B | 8.44 | -% | 39.4% | $72.43 | Compare |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
BEARISH | $5.82B | - | -8.6% | -4.5% | $96.49 | Compare |
|
RGEN
Repligen Corporation
|
NEUTRAL | $6.64B | 137.0 | 2.4% | 6.6% | $117.82 | Compare |
RYTM
Rhythm...
NEUTRAL
Mkt Cap
$6.1B
P/E
-
ROE
-90.5%
Price
$88.69
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | MAZABRAUD YANN | Officer | Stock Award | 12,875 | - |
| 2026-03-04 | GERMAN CHRISTOPHER PAUL | Officer | Sale | 5,614 | $502,790 |
| 2026-03-04 | GERMAN CHRISTOPHER PAUL | Officer | Option Exercise | 1,500 | $26,955 |
| 2026-03-02 | SMITH HUNTER C | Chief Financial Officer | Option Exercise | 6,099 | $41,473 |
| 2026-02-27 | GERMAN CHRISTOPHER PAUL | Officer | Stock Award | 1,162 | - |
| 2026-02-13 | MAZABRAUD YANN | Officer | Stock Award | 10,000 | - |
| 2026-02-12 | SMITH HUNTER C | Chief Financial Officer | Sale | 7,071 | $708,576 |
| 2026-02-05 | SMITH HUNTER C | Chief Financial Officer | Sale | 6,628 | $702,744 |
| 2026-01-30 | LEE JENNIFER KAYDEN | Officer | Stock Award | 22,612 | - |
| 2026-01-30 | CRAMER PAMELA J. | Officer | Stock Award | 13,293 | - |
| 2026-01-30 | SHULMAN JOSEPH J | Chief Technology Officer | Stock Award | 16,968 | - |
| 2026-01-30 | GERMAN CHRISTOPHER PAUL | Officer | Stock Award | 3,613 | - |
| 2026-01-30 | GARFIELD ALASTAIR PH.D. | Officer | Stock Award | 6,663 | - |
| 2026-01-30 | MEEKER DAVID P | Chief Executive Officer | Stock Award | 68,713 | - |
| 2026-01-30 | SMITH HUNTER C | Chief Financial Officer | Stock Award | 26,000 | - |
MAZABRAUD YANN
Officer
2026-04-01
12,875 shares
GERMAN CHRISTOPHER PAUL
Officer
2026-03-04
5,614 shares
·
$502,790
GERMAN CHRISTOPHER PAUL
Officer
2026-03-04
1,500 shares
·
$26,955
SMITH HUNTER C
Chief Financial Officer
2026-03-02
6,099 shares
·
$41,473
GERMAN CHRISTOPHER PAUL
Officer
2026-02-27
1,162 shares
MAZABRAUD YANN
Officer
2026-02-13
10,000 shares
SMITH HUNTER C
Chief Financial Officer
2026-02-12
7,071 shares
·
$708,576
SMITH HUNTER C
Chief Financial Officer
2026-02-05
6,628 shares
·
$702,744
LEE JENNIFER KAYDEN
Officer
2026-01-30
22,612 shares
CRAMER PAMELA J.
Officer
2026-01-30
13,293 shares
SHULMAN JOSEPH J
Chief Technology Officer
2026-01-30
16,968 shares
GERMAN CHRISTOPHER PAUL
Officer
2026-01-30
3,613 shares
GARFIELD ALASTAIR PH.D.
Officer
2026-01-30
6,663 shares
MEEKER DAVID P
Chief Executive Officer
2026-01-30
68,713 shares
SMITH HUNTER C
Chief Financial Officer
2026-01-30
26,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
15 analysts
HC Wainwright & Co.
2026-03-23
Buy
Buy
Citigroup
2026-03-20
Buy
Buy
B of A Securities
2026-03-20
Buy
Buy
Citizens
2026-03-20
Market Outperform
Market Outperform
HC Wainwright & Co.
2026-03-18
Buy
Buy
Citigroup
2026-03-17
Buy
Buy
RBC Capital
2026-03-17
Outperform
Outperform
Citizens
2026-03-17
Market Outperform
Market Outperform
B of A Securities
2026-03-17
Buy
Buy
Morgan Stanley
2026-03-17
Overweight
Overweight
Past News Coverage
Recent headlines mentioning RYTM from our newsroom.
Newest → oldest
No matching news yet.